Posts
Bullish long-term on CELH (Celsius & Alani)
Celsius valuation looking like a strong setup for the rest of the year. Also, another benefit is that it’s NOT the Ai trade. Alani NU is not competing for the same shelf, it’s opening a whole new door. It’s been THE drink for Gen Z and millennial women. Go look …
CELH - too much growth priced in?
When I started my deep dive into Celsius holdings, I was very much expecting the output to indicate a quality company trading at attractive prices. As I learnt about the company, I started liking them more and more. However, when I finally completed my model, I was surprised to see …
compounders
I see a lot of low growth companies mentioned in this sub What are some companies that can actually grow earnings by 10-30% per year for the next decade and are in your opinion reasonable valued? I’ll start \- planisware (French planning software) \- Nedap (software, security, agriculture, inventory management) …
Any good deals based on price to true fcf?
FCF (“Owner’s earnings”) =\~ Cash From Operating - CapEx - SBC I missed the oppty to buy $DBX at 10-12x FCF. I even posted about it here and now it’s run up like 25%+ 😾 lol I rarely see “value” discussed here in a strict quantitative ie non narrative basis. …
Eli Lilly’s GLP-1 machine is still running hot
$LLY Q2 2026: Revenue: $22.97B vs. $20.26B expected Revenue growth: +48% Non-GAAP EPS: $8.38 vs. $6.01 expected Reported net income: $7.10B, up 25% Non-GAAP net income: $7.49B, up 32% The main drivers were Mounjaro and Zepbound. Mounjaro revenue rose 91% to $9.94B. U.S. Mounjaro revenue rose 45% to $4.8B. International …
A 17-step deep-dive research process
*Since the sub does not allow any images I am linking my substack where I’ve compiled all the points into a downloadable image for easier reference:* *This is a buy side institutional grade research process that we follow at my firm. Some points may not be directly relevant to everyone, …
Anyone looking at OPRA?
I’ve been looking at Opera (OPRA) recently as a potential valueplay and wanted to see if anyone on this sub has looked into them. The value I am seeing: **Valuation & Multiples:** Trades at \~14x forward P/E (\~13.5x EV/EBITDA) despite growing top-line revenue by 20%+ YoY. **Free Cash Flow & …